Altmetrics: Is it Gaining Traction as a Measure of Research Impact?

In July 2014, without any fan fare, we embedded the donut-shaped Altmetric Badge as a new feature on Synapse (MSK Publication database). What this new feature provides to the viewer, when available, is a way to measure the online attention received by a particular work, with the option to be alerted whenever the work receives any new mentions. The Altmetric score is “derived from an automated algorithm, and represents a weighted count of the amount of attention ….. picked up for a research output.” Readers and authors can click on the donut score to be taken to the details page for that specific work where they can further explore all the original mentions and sources. The Altmetric Donut Badge is not unique to Synapse; it can also be found on a variety of publishers’ platforms including Elsevier, Springer Nature, and PLoS.

Altmetrics, or alternative metrics, introduced a new approach to determine the value, impact, or popularity of research within the digital scholarly ecosystem. These web-based metrics come in the form of tallied views, downloads, cites, saves, bookmarks, tweets, shares, likes, recommends, posts, comments, and tags.  Tweets, for example are displayed in the context of a map showing the global Twitter reach of the work. You can also review the News tab to see which news outlets picked up the published research to share beyond the scientific community.  Available information is delivered in real time and can change daily.  Continue reading

Music Mogol Creates Cancer Institute, New Ovarian Cancer Vaccine in Trial at MSK, “Smart” Hospitals, and Immigrant Health

Napster co-Founder Sean Parker is donating $250 million dollars to create the Parker Institute for Cancer Immunotherapy, a collaboration of six leading academic centers ,including MSK, to pave the way to develop new therapies to use patient’s own immune systems to fight cancer. The Institute will  share research materials and discoveries and jointly conduct clinical trials to try to accelerate progress. “How do we get more therapies to market faster and more cheaply?” Mr. Parker said in an interview, adding that his effort represented a new “blueprint for biomedical research funding.”


MSK will be hosting a new phase 2 clinical trial study for ovarian cancer starting this summer with TapImmune and AstraZeneca/MedImmune. The trial will be of TapImmune’s cancer vaccine TPIV 200, a multi-epitope anti-folate receptor vaccine (FRα), in combination with AstraZeneca’s durvalumab , an anti-PD-L1 antibody, in patients with platinum-resistant ovarian cancer. Continue reading

Introduction to Epidemiology, 7e is NEW!

The seventh edition of Introduction to Epidemiology is a comprehensive introduction to the field. It is designed for students with minimal training in the biomedical sciences and statistics and emphasizes the application of the basic principles of epidemiology in order to solve current and serious public health problems. Students will learn how to

  • identify and describe public health problems,
  • formulate research hypotheses,
  • select appropriate research study designs,
  • manage and analyze epidemiologic data,
  • interpret results, and
  • apply results in preventing and controlling disease and health-related events.
  • Continue reading